首页> 外文期刊>Journal of Ultrasound >Hepatocellular carcinoma tumor thrombus entering the inferior vena cava treated with percutaneous RF ablation: a case report
【24h】

Hepatocellular carcinoma tumor thrombus entering the inferior vena cava treated with percutaneous RF ablation: a case report

机译:经皮射频消融治疗进入下腔静脉的肝细胞癌肿瘤血栓:一例报告

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose Hepatocellular carcinoma (HCC) is the most common form of liver cancer. In advanced cancer stages (metastatic disease and/or vascular invasion), the generally accepted standard of care is systemic therapy using sorafenib as first-line treatment and, recently, regorafenib and nivolumab as second-line treatment, but the quality of life and the prognosis of patients remain very poor. Our paper reports a case of US-guided radiofrequency ablation (RFA) of both intraparenchymal HCC and inferior vena cava tumor thrombus. Methods We treated a patient with HCC associated with tumor thrombus extending into vena cava after failure of sorafenib therapy using US-guided radiofrequency ablation (RFA). Results A good radiological and clinical response was observed in association with excellent tolerability. The patient has been followed up for 15 months from the ablation, is alive, and is in a good clinical condition without evidence of tumor recurrence. Conclusion This is the first case in which this minimally invasive percutaneous procedure has been successfully used to treat an HCC thrombus entering the vena cava.
机译:目的肝细胞癌(HCC)是最常见的肝癌形式。在晚期癌症阶段(转移性疾病和/或血管侵犯),普遍接受的护理标准是使用索拉非尼作为一线治疗,最近使用雷戈非尼和尼古鲁单抗作为二线治疗的全身治疗,但是生活质量和患者的预后仍然很差。我们的论文报道了一例实质性肝癌和下腔静脉肿瘤血栓的美国指导的射频消融术。方法我们采用美国引导的射频消融术(RFA)治疗索拉非尼治疗失败后伴有血栓扩展至腔静脉的HCC患者。结果观察到良好的放射学和临床反应,并具有优异的耐受性。消融后已随访患者15个月,还活着,并且处于良好的临床状态,没有肿瘤复发的迹象。结论这是首次将这种微创经皮手术成功用于治疗进入腔静脉的HCC血栓的病例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号